for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Relief Therapeutics says Zyesami to be included in COVID-19 clinical trial

ZURICH, Jan 11 (Reuters) - Relief Therapeutics said its partner NeuroRx and the Quantum Leap Healthcare Collaborative signed an agreement to include Zyesami in the I-SPY COVID-19 clinical trial, a platform trial assessing multiple drugs for critically ill COVID-19 patients.

Zyesami will be included as one of the first drugs targeting respiratory failure in critically ill COVID-19 patients, Relief Therapeutics said in a statement on Monday. (Reporting by Silke Koltrowitz; editing by Thomas Seythal)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up